首页 > R&D Systems > R&D Systems/Recombinant Human GM-CSF Protein/215-GM-500/500 ug

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

R&D Systems/Recombinant Human GM-CSF Protein/215-GM-500/500 ug

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

215-GM-500-500ug

品牌：

R&D Systems

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Purity>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.Endotoxin LevelActivityMeasured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED50 for this effect is 6-30 pg/mL.The specific activity of Recombinant Human GM-CSF is approximately 1.5 x 104 IU/μg, which is calibrated against human GM-CSF WHO International Standard (NIBSC code: 88/646).SourceE. coli-derived Ala18-Glu144Accession #CAA26822 N-terminal Sequence AnalysisAla18Predicted Molecular Mass14 kDa References:Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653. Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509. Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163. Cao, Y. (2007) J. Clin. Invest. 117:2362. Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.Heuser, M. et al. (2007) Semin. Hematol. 44:148. Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321. Kaushansky, K. et al. (1992) Biochemistry 31:1881. Diederichs, K. et al. (1991) Science 254:1779. Cantrell, M.A. et al. (1985) Proc. Natl. Acad. Sci. 82:6250. Lee, F. et al. (1985) Proc. Natl. Acad. Sci. 82:4360. Wong, G.G. et al. (1985) Science 228:810. Onetto-Pothier, N. et al. (1990) Blood 75:59. Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655. Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483. Hogge, G.S. et al. (1990) Cancer Gene Ther. 6:26. Sprague, W.S. et al. (2005) J. Comp. Pathol. 133:136. Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.Long Name:Granulocyte Macrophage Growth FactorEntrez Gene IDs:1437 (Human); 12981 (Mouse); 116630 (Rat); 397208 (Porcine); 403923 (Canine); 493805 (Feline)Alternate Names:colony stimulating factor 2 (granulocyte-macrophage); Colony-stimulating factor; CSF; CSF2; GMCSF; GM-CSF; GMCSFgranulocyte-macrophage colony-stimulating factor; granulocyte-macrophage colony stimulating factor; MGC131935; MGC138897; molgramostin; sargramostimBackground:GM‑CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte‑macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM‑CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM‑CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM‑CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3‑5). It shows clinical effectiveness in ameliorating chemotherapy‑induced neutropenia, and GM‑CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM‑CSF, similar to IL‑3 and IL‑5, is a cytokine with a core of four bundled alpha -helices (8‑12). Mature human GM‑CSF shares 63%‑70% amino acid sequence identity with canine, feline, porcine, and rat GM‑CSF and 54% with mouse GM‑CSF. GM‑CSF exerts its biological effects through a heterodimeric receptor complex composed of GM‑CSF R alpha /CD116 and the signal transducing commonbeta chain (CD131) which is also a component of the high‑affinity receptors for IL‑3 and IL‑5 (13, 14). In addition, GM‑CSF binds a naturally occurring soluble form of GM‑CSF R alpha(15). Human GM‑CSF is active on canine and feline cells but not on murine cells (16‑18).

R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。